194 related articles for article (PubMed ID: 38285081)
1. Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review.
Wang Q; Zhao Y; Zang X; Zhou G; Liu Y; Feng Q; Li X; Wang W; Dong X; Liu X; Peng J; Liu C
Ann Hematol; 2024 Mar; 103(3):999-1005. PubMed ID: 38285081
[TBL] [Abstract][Full Text] [Related]
2. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
[TBL] [Abstract][Full Text] [Related]
3. [Blastic plasmacytoid dendritic cell tumor treated with DVT regimen: a case report and literature review].
Shi J; Xu N; Niu Y; Jia SX; Yang CM; Fang MY
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):86-89. PubMed ID: 38527844
[TBL] [Abstract][Full Text] [Related]
4. Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm.
Nagate Y; Nakaya A; Kamimura R; Hirose Y; Nojima S; Fujita J; Kiyohara E; Shibayama H
Intern Med; 2023; 62(17):2547-2551. PubMed ID: 37661416
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) - a new perspective.
Mirgh S; Sharma A; Folbs B; Khushoo V; Kapoor J; Tejwani N; Ahmed R; Agrawal N; Choudhary PS; Mehta P; Bhurani D
Leuk Lymphoma; 2021 Dec; 62(12):3039-3042. PubMed ID: 34151693
[No Abstract] [Full Text] [Related]
6. Achievement of rapid complete remission in an 87-year-old female patient with azacytidine-venetoclax for blastic plasmacytoid dendritic cell neoplasm.
Le Calloch R; Arnaud B; Le Clech L; Hutin P; Salmon F; Garnache Ottou F; Ianotto JC; Laribi K
Ann Hematol; 2022 Jun; 101(6):1347-1349. PubMed ID: 35249131
[No Abstract] [Full Text] [Related]
7. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
Montero J; Stephansky J; Cai T; Griffin GK; Cabal-Hierro L; Togami K; Hogdal LJ; Galinsky I; Morgan EA; Aster JC; Davids MS; LeBoeuf NR; Stone RM; Konopleva M; Pemmaraju N; Letai A; Lane AA
Cancer Discov; 2017 Feb; 7(2):156-164. PubMed ID: 27986708
[TBL] [Abstract][Full Text] [Related]
8. Frontline Hyper-CVAD Plus Venetoclax for Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm.
He J; Garcia MB; Connors JS; Nuñez CA; Quesada AE; Gibson A; Roth M; Cuglievan B; Pemmaraju N; McCall D
J Pediatr Hematol Oncol; 2023 Nov; 45(8):e1001-e1004. PubMed ID: 37661300
[TBL] [Abstract][Full Text] [Related]
9. Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm.
Piccini M; Loscocco GG; Gianfaldoni G; Grieco P; Palmieri G; Pilerci S; Scappini B; Bosi A
Ann Hematol; 2020 Apr; 99(4):907-909. PubMed ID: 32030448
[No Abstract] [Full Text] [Related]
10. Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm.
Schwede M; Tan IT; Atibalentja DF; Dickman MM; Rieger KE; Mannis GN
Ann Hematol; 2020 Dec; 99(12):2973-2975. PubMed ID: 32968828
[No Abstract] [Full Text] [Related]
11. Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature.
Albiol N; Novelli S; Mozos A; Pratcorona M; Martino R; Sierra J
J Med Case Rep; 2021 Jun; 15(1):326. PubMed ID: 34172079
[TBL] [Abstract][Full Text] [Related]
12. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.
Egger A; Coello D; Kirsner RS; Brehm JE
J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
[TBL] [Abstract][Full Text] [Related]
13. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jain A; Sweet K
J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
[TBL] [Abstract][Full Text] [Related]
14. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a rare entity.
Lim MS; Lemmert K; Enjeti A
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26791132
[TBL] [Abstract][Full Text] [Related]
15. Novel treatment of blastic plasmacytoid dendritic cell neoplasm: A case report.
Grushchak S; Joy C; Gray A; Opel D; Speiser J; Reserva J; Tung R; Smith SE
Medicine (Baltimore); 2017 Dec; 96(51):e9452. PubMed ID: 29390581
[TBL] [Abstract][Full Text] [Related]
16. CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123.
Hu X; Ediriwickrema A; Saleem A; Tan B; Pemmaraju N; Mannis GN
Leuk Res; 2024 Apr; 139():107479. PubMed ID: 38492495
[No Abstract] [Full Text] [Related]
17. Diagnosis, treatment, and genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A review.
Wang Y; Xiao L; Yin L; Zhou L; Deng Y; Deng H
Medicine (Baltimore); 2023 Feb; 102(7):e32904. PubMed ID: 36800625
[TBL] [Abstract][Full Text] [Related]
18. Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123.
Zanotta S; Galati D; De Filippi R; Pinto A
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338733
[TBL] [Abstract][Full Text] [Related]
19. Mutated ZRSR2 and CUL3 accelerate clonal evolution and confer venetoclax resistance via RAS signaling pathway in blastic plasmacytoid dendritic cell neoplasm.
Fukuchi K; Koyama D; Takada M; Mori H; Hayashi K; Asano N; Sato Y; Fukatsu M; Takano M; Takahashi H; Shirado-Harada K; Kimura S; Yamamoto T; Ikezoe T
Int J Hematol; 2023 Oct; 118(4):489-493. PubMed ID: 37029861
[TBL] [Abstract][Full Text] [Related]
20. A case of blastic plasmacytoid dendritic cell neoplasm with ecchymotic lesions on the whole body.
Cui XB; Jin J; Pang XL; Li S; Liu CX; Li TT; Peng H; Zhang SM; Li L; Liang WH; Chen YZ; Li F
Int J Clin Exp Pathol; 2014; 7(7):4391-9. PubMed ID: 25120824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
